And IMU has been developing its pipeline of discoveries for 13 years with a market cap of around $417m. Has done a truck load of investor presentations, conferences, road shows, peer reviews yet no BIG Pharma has come to the table to date. IMU could be a multi bagger, however, that could be years away.
SNT is a flyweight contesting in a heavy weight division with a MC of $34m with bugger all revenue and importantly net or profit margin of minus 1,069% up nearly 50% on the last quarter (March 2024) with net income minus $4.3m, up about 13% (last quarter).
As an SNT investor I hope it is successful however, the only way forward without losing its IP is consider merging with another ASX pharma company IMO.
Add to My Watchlist
What is My Watchlist?
